Journal articles: 'HIV infections Treatment Victoria'

1

Falster, Kathleen, Linda Gelgor, Ansari Shaik, Iryna Zablotska, Garrett Prestage, Jeffrey Grierson, Rachel Thorpe, et al. "Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment." Sexual Health 5, no. 2 (2008): 141. http://dx.doi.org/10.1071/sh07082.

Full text

Abstract:

Objectives: To determine if there were any differences in antiretroviral treatment (ART) use across the three eastern states of Australia, New South Wales (NSW), Victoria and Queensland, during the period 1997 to 2006. Methods: We used data from a clinic-based cohort, the Australian HIV Observational Database (AHOD), to determine the proportion of HIV-infected patients on ART in selected clinics in each state and the proportion of treated patients with an undetectable viral load. Data from the national Highly Specialised Drugs program and AHOD were used to estimate total numbers of individuals on ART and the proportion of individuals living with HIV on ART nationally and by state. Data from the HIV Futures Survey and the Gay Community Periodic Survey were used to determine the proportion of community-based men who have sex with men on ART. The proportion of patients with primary HIV infection (PHI) who commenced ART within 1 year of diagnosis was obtained from the Acute Infection and Early Disease Research Program (AIEDRP) CORE01 protocol and Primary HIV and Early Disease Research: Australian Cohort (PHAEDRA) cohorts. Results: We estimated that the numbers of individuals on ART increased from 3181 to 4553 in NSW, 1309 to 1926 in Victoria and 809 to 1615 in Queensland between 2000 and 2006. However, these numbers may reflect a lower proportion of individuals living with HIV on ART in NSW compared with the other states (37% compared with 49 and 55% in 2000). We found similar proportions of HIV-positive men who have sex with men participants were on ART in all three states over the study period in the clinic-based AHOD cohort (81–92%) and two large, community-based surveys in Australia (69–85% and 49–83%). Similar proportions of treated patients had an undetectable viral load across the three states, with a consistently increasing trend over time observed in all states. We found that more PHI patients commenced treatment in the first year following HIV diagnosis in NSW compared with Victoria; however, the sample size was very small. Conclusions: For the most part, patterns of ART use were similar across NSW, Victoria and Queensland using a range of available data from cohort studies, community surveys and national prescription databases in Australia. However, there may be a lower proportion of individuals living with HIV on ART in NSW compared with the other states, and there is some indication of a more aggressive treatment approach with PHI patients in NSW compared with Victoria.

APA, Harvard, Vancouver, ISO, and other styles

2

Hoare, Alexander, David P. Wilson, David G. Regan, John Kaldor, and Matthew G. Law. "Using mathematical modelling to help explain the differential increase in HIV incidence in New South Wales, Victoria and Queensland: importance of other sexually transmissible infections." Sexual Health 5, no. 2 (2008): 169. http://dx.doi.org/10.1071/sh07099.

Full text

Abstract:

Background: Since 1999 there has been an increase in the number of HIV diagnoses in Australia, predominantly among men who have sex with men (MSM), but the magnitude of increase differs between states: ~7% rise in New South Wales, ~96% rise in Victoria, and ~68% rise in Queensland. Methods: Epidemiological, clinical, behavioural and biological data were collated into a mechanistic mathematical model to explore possible reasons for this increase in HIV notifications in MSM. The model was then used to make projections to 2015 under various scenarios. Results: The model suggests that trends in clinical and behavioural parameters, including increases in unprotected anal intercourse, cannot explain the magnitude of the observed rise in HIV notifications, without a substantial increase in a ‘transmission-increasing’ factor. We suggest that a highly plausible biological factor is an increase in the prevalence of other sexually transmissible infections (STI). It was found that New South Wales required an ~2-fold increase in other STI to match the data, Victoria needed an ~11-fold increase, and Queensland required an ~9-fold increase. This is consistent with observed trends in Australia for some STI in recent years. Future projections also indicate that the best way to control the current rise in HIV notifications is to reduce the prevalence of other STI and to promote condom use, testing for HIV, and initiation of early treatment in MSM diagnosed during primary infection. Conclusions: Our model can explain the recent rise in HIV notifications with an increase in the prevalence of other STI. This analysis highlights that further investigation into the causes and impact of other STI is warranted in Australia, particularly in Victoria.

APA, Harvard, Vancouver, ISO, and other styles

3

Guy, Rebecca J., Ann M. McDonald, Mark J. Bartlett, Jo C. Murray, Carolien M. Giele, Therese M. Davey, Ranil D. Appuhamy, et al. "Characteristics of HIV diagnoses in Australia, 1993-2006." Sexual Health 5, no. 2 (2008): 91. http://dx.doi.org/10.1071/sh07070.

Full text

Abstract:

Objective: To describe recent trends in the diagnosis of HIV infection in Australia. Methods: National HIV surveillance data from 1993 to 2006 were analysed with a focus on geographic differences by HIV exposure route and late presentation (HIV within 3 months of a first AIDS-defining illness or a CD4 count of less than 200 cells μL–1). Results: In 1993–99, the number of HIV diagnoses declined by 32%, and then increased by 39% from 1999 to 2006. From 2000 onwards, rates increased significantly in Victoria, Queensland, South Australia and Western Australia. The most frequently reported routes of HIV exposure were male to male sex (71%) and heterosexual contact (18%), and the population rate of diagnoses have increased in both categories. Among the cases reported as heterosexually acquired (n = 2199), 33% were in people born in a high-prevalence country and 19% in those with partners from a high-prevalence country. Late presentation was most frequent in heterosexually acquired infections in persons who had a partner from a high-prevalence country: 32% compared with 20% overall. Conclusions: Recent increases in annual numbers of HIV diagnoses in Australia underline the continuing need for HIV-prevention programs, particularly among men having male to male sex. Early diagnosis and access to care and treatment should also be emphasised, as a substantial proportion of people with HIV infection are unaware of their status until late in the course of disease.

APA, Harvard, Vancouver, ISO, and other styles

4

Iddi, Shabani, Caroline A. Minja, Vitus Silago, Asteria Benjamin, Jastine Mpesha, Shimba Henerico, Benson R. Kidenya, Stephen E. Mshana, and Mariam M. Mirambo. "High Human Immunodeficiency Virus (HIV) Viral Load and Coinfection with Viral Hepatitis Are Associated with Liver Enzyme Abnormalities among HIV Seropositive Patients on Antiretroviral Therapy in the Lake Victoria Zone, Tanzania." AIDS Research and Treatment 2019 (June 2, 2019): 1–6. http://dx.doi.org/10.1155/2019/6375714.

Full text

Abstract:

Background. Liver enzymes abnormalities have been found to be common among patients on antiretroviral treatment (ART). Apart from the effects of ART on these changes, other factors that can potentially contribute to the abnormal levels of these enzymes have been found to vary in different geographical locations. This study investigated factors associated with liver enzymes abnormalities among human immunodeficiency virus (HIV) infected individuals on ART from the Lake Victoria zone, Tanzania. Methods. A cross-sectional study involving a total of 230 sera from HIV seropositive patients from different regions of the Lake Victoria zone was carried out in July 2017. All samples with required variables/parameters such as age, sex, ART regimen, and residence were serially included in the study. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) detection and liver enzymes assays (alanine transaminase (ALAT) and aspartate transaminase (ASAT)) were assessed following the standard procedures. Data were analyzed by using STATA version 13. Results. The median age of the study participants was 38 (interquartile range [IQR]:30-48) years. The overall prevalence of abnormal liver enzymes was 43.04% (99/230, 95% CI: 36.6-49.3). A total of 26.09% (60/230) had elevated ASAT while 23.9% (55/230) patients had elevated ALAT levels. ASAT levels were significantly high among patients with high HIV viral load (P= 0.002) while ALAT levels were significantly high among those coinfected with hepatitis C virus (P=0.017) and hepatitis B virus (P<0.001). Conclusion. A significant proportion of HIV seropositive individuals on ART have abnormal levels of liver enzymes, which is significantly associated with high HIV viral load and viral hepatitis. This calls for the need to emphasize screening of viral hepatitis and provision of appropriate management among HIV seropositive individuals in this setting.

APA, Harvard, Vancouver, ISO, and other styles

5

Tumwine, Christopher, Peter Aggleton, and Stephen Bell. "Enhancing HIV Prevention: Social Support, Access to, and Use of HIV Testing, Treatment, and Care Services in Fishing Communities Around Lake Victoria, Uganda." AIDS Education and Prevention 32, no. 3 (June 2020): 196–211. http://dx.doi.org/10.1521/aeap.2020.32.3.196.

Full text

Abstract:

In-depth interviews were conducted with 42 HIV-positive fisherfolk and 15 health care providers to identify experiences of social support and its influence on access to and use of HIV testing, treatment, and care. Fisherfolk participants reported receiving support at some point. Prior to HIV diagnosis, this usually took the form of advice on what illness they were dealing with and remedies to use. After HIV diagnosis and disclosure to friends or family, emotional support enabled fisherfolk to come to terms with an HIV diagnosis, informational support offered guidance on how best to live with HIV, while instrumental support enabled access to relevant HIV services. Finally, affiliative support, in the form of new friends met through HIV clinic visits, provided a sense of belonging. Each of these different kinds of support assisted fisherfolk to respond positively to HIV with important consequences for secondary and tertiary prevention.

APA, Harvard, Vancouver, ISO, and other styles

6

Wilkinson, Anna L., Bridget L. Draper, Alisa E. Pedrana, Jason Asselin, Martin Holt, Margaret E. Hellard, and Mark Stoové. "Measuring and understanding the attitudes of Australian gay and bisexual men towards biomedical HIV prevention using cross-sectional data and factor analyses." Sexually Transmitted Infections 94, no. 4 (November 21, 2017): 309–14. http://dx.doi.org/10.1136/sextrans-2017-053375.

Full text

Abstract:

IntroductionContemporary responses to HIV embrace biomedical prevention, particularly treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP). However, large-scale implementation of biomedical prevention should be ideally preceded by assessments of their community acceptability. We aimed to understand contemporary attitudes of gay and bisexual men (GBM) in Australia towards biomedical-based HIV prevention and propose a framework for their measurement and ongoing monitoring.MethodsA cross-sectional, online survey of GBM ≥18 years has been conducted annually in Victoria, Australia, since 2008. In 2016, 35 attitudinal items on biomedical HIV prevention were added. Items were scored on five-point Likert scales. We used principal factor analysis to identify key constructs related to GBM’s attitudes to biomedical HIV prevention and use these to characterise levels of support for TasP and PrEP.ResultsA total of 462 HIV-negative or HIV-status-unknown men, not using PrEP, provided valid responses for all 35 attitudinal items. We extracted four distinct and interpretable factors we named: ‘Confidence in PrEP’, ‘Judicious approach to PrEP’, ‘Treatment as prevention optimism’ and ‘Support for early treatment’. High levels of agreement were seen across PrEP-related items; 77.9% of men agreed that PrEP prevented HIV acquisition and 83.6% of men agreed that users were protecting themselves. However, the agreement levels for HIV TasP items were considerably lower, with <20% of men agreeing treatment (undetectable viral load) reduced HIV transmission risk.ConclusionsBetter understanding of community attitudes is crucial for shaping policy and informing initiatives that aim to improve knowledge, acceptance and uptake of biomedical prevention. Our analyses suggest confidence in, acceptability of and community support for PrEP among GBM. However, strategies to address scepticism towards HIV treatment when used for prevention may be needed to optimise combination biomedical HIV prevention.

APA, Harvard, Vancouver, ISO, and other styles

7

Abaasa, Andrew, Gershim Asiki, Andrew Obuku Ekii, Josephine Wanyenze, Pietro Pala, Govert J. van Dam, Paul L.A.M. Corstjens, et al. "Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and Schistosoma mansoni co-infected patients: a randomised controlled trial." Wellcome Open Research 3 (July 5, 2018): 81. http://dx.doi.org/10.12688/wellcomeopenres.14683.1.

Full text

Abstract:

Background: It has been hypothesised that Schistosoma co-infection exacerbates HIV progression, and hence anthelminthic intervention in co-infected individuals will delay it. We evaluated effects of high-intensity versus low-intensity praziquantel treatment of schistosomiasis on HIV disease progression among co-infected patients from fishing populations around Lake Victoria, Uganda. Methods: Between August 2012 and September 2015, we conducted an open-label randomised, controlled trial. Adults, antiretroviral therapy-naïve, CD4 counts ≥350 cells/μl, HIV and S. mansoni co-infected, were randomised 1:1 to praziquantel (40mg/kg) given quarterly (starting at enrolment) or annually (starting 12 weeks after enrolment; such that low-intensity participants were still untreated when sampled at 12 weeks). A non-randomised HIV-positive S. mansoni-negative comparison group was recruited. The primary outcome was mean change in plasma viral load at 12 and 60 weeks. Results: In total 363 participants (high-intensity 113, low-intensity 113, comparison group 137) were recruited; 96 (85.0%), 97 (85.8%) and 107 (78.1%) completed 60 weeks of follow up, respectively. Adjusting for baseline age and viral load, the geometric mean ratio (aGMR [95%CI]) viral load for high-intensity vs low-intensity groups at 12 weeks was 0.90 [0.65, 1.25] p=0.55 and at 60 weeks 1.88 [0.78, 4.53] p=0.16. Results in the comparison group were similar to trial arms. High-intensity, compared to low-intensity, treatment resulted in substantially lower S. mansoni prevalence at all follow up visits (p<0.05). Conclusions: In communities with a high burden of both S. mansoni and HIV infection, high-intensity treatment of S. mansoni does not delay HIV progression despite relevant benefit for parasite clearance. Trial registration: ISRCTN15371662 (17/11/2016)

APA, Harvard, Vancouver, ISO, and other styles

8

Abaasa, Andrew, Gershim Asiki, Andrew Obuku Ekii, Josephine Wanyenze, Pietro Pala, Govert J. van Dam, Paul L. A. M. Corstjens, et al. "Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and Schistosoma mansoni co-infected patients: a randomised controlled trial." Wellcome Open Research 3 (April 3, 2019): 81. http://dx.doi.org/10.12688/wellcomeopenres.14683.2.

Full text

Abstract:

Background: It has been hypothesised that Schistosoma co-infection exacerbates HIV progression, and hence anthelminthic intervention in co-infected individuals will delay it. We evaluated effects of high-intensity versus low-intensity praziquantel treatment of schistosomiasis on HIV disease progression among co-infected patients from fishing populations around Lake Victoria, Uganda. Methods: Between August 2012 and September 2015, we conducted an open-label randomised, controlled trial. Adults, antiretroviral therapy-naïve, CD4 counts ≥350 cells/μl, HIV and S. mansoni co-infected, were randomised 1:1 to praziquantel (40mg/kg) given quarterly (starting at enrolment) or annually (starting 12 weeks after enrolment; such that low-intensity participants were still untreated when sampled at 12 weeks). A non-randomised HIV-positive S. mansoni-negative comparison group was recruited. The primary outcome was mean change in plasma viral load at 12 and 60 weeks. Results: In total 363 participants (high-intensity 113, low-intensity 113, comparison group 137) were recruited; 96 (85.0%), 97 (85.8%) and 107 (78.1%) completed 60 weeks of follow up, respectively. Adjusting for baseline age and viral load, the geometric mean ratio (aGMR [95%CI]) viral load for high-intensity vs low-intensity groups at 12 weeks was 0.90 [0.65, 1.25] p=0.55 and at 60 weeks 1.88 [0.78, 4.53] p=0.16. Results in the comparison group were similar to trial arms. High-intensity, compared to low-intensity, treatment resulted in substantially lower S. mansoni prevalence at all follow up visits (p<0.05). Conclusions: In communities with a high burden of both S. mansoni and HIV infection, high-intensity treatment of S. mansoni does not delay HIV progression despite relevant benefit for parasite clearance. Trial registration: ISRCTN15371662 (17/11/2016)

APA, Harvard, Vancouver, ISO, and other styles

9

D'Costa, Jodie, Megan Gooey, Nicole Richards, Rizmina Sameer, Elaine Lee, and Doris Chibo. "Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new." Sexual Health 14, no. 6 (2017): 558. http://dx.doi.org/10.1071/sh16190.

Full text

Abstract:

Background Baseline genotyping is part of standard-of-care treatment. It reveals that transmitted drug resistance (TDR) continues to be important for the management of HIV infection. Attention is typically focused on determining whether resistance to the protease inhibitors (PI) and reverse transcriptase inhibitors (RTI) occurs. However, the increasing use of integrase inhibitors (INIs) raises a concern that TDR to this class of antiretroviral drug may also occur. Methods: PI and RTI drug resistance genotyping was performed on blood samples collected between 2005 and 2015 from 772 treatment-naïve Victorian patients infected with HIV within the previous 12 months. Integrase genotyping was performed on 461 of the 485 patient samples collected between 2010 and 2015. Results: In the period 2005–10, 39 of 343 patients (11.4%) had at least one PI- or RTI-associated mutation, compared with 34 of 429 (7.9%) during the period 2011–15. Compared with 2005–10, during 2011–15 there was a significant decline in the prevalence of the non-nucleoside-associated mutation K103N and the nucleoside-associated mutations at codons M41 and T215. One patient was detected with a major INI resistance mutation, namely G118R. However, this mutation is rare and its effect on susceptibility is unclear. A small number of patients (n = 12) was infected with HIV containing accessory resistance mutations in the integrase gene. Conclusions: The lack of transmitted resistance to INIs is consistent with a low level of resistance to this class of drugs in the treated population. However, continued surveillance in the newly infected population is warranted as the use of INIs increases.

APA, Harvard, Vancouver, ISO, and other styles

10

Tumwine, Christopher, Peter Aggleton, and Stephen Bell. "Accessing HIV treatment and care services in fishing communities around Lake Victoria in Uganda: mobility and transport challenges." African Journal of AIDS Research 18, no. 3 (September 27, 2019): 205–14. http://dx.doi.org/10.2989/16085906.2019.1648306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Hanke, Tomáš, Patricia Fast, Pontiano Kaleebu, Walter Jaoko, Eduard Sanders, William Kilembe, Hester Kuipers, Brenda Okech, and Jill Gilmour. "OC 8499 THE T-CELL VACCINE STRATEGY: GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT)." BMJ Global Health 4, Suppl 3 (April 2019): A10.3—A11. http://dx.doi.org/10.1136/bmjgh-2019-edc.25.

Full text

Abstract:

BackgroundRemarkable progress has been achieved in decreasing AIDS-related deaths and HIV-1 transmission through ART. Nevertheless, an affordable, effective and durable HIV-1 vaccine protection remains the best solution for halting the AIDS epidemic.Our aim is to develop a vaccine inducing cytotoxic T lymphocytes (CTL), which effectively inhibit HIV-1 replication and complement bnAbs for prevention; such T cells are likely critical for a successful cure. Central to our strategy is to focus HIV-1-specific CTL on the most functionally conserved regions (not a string of epitopes and not full-length proteins) common to most HIV-1 variants, which HIV-1 typically cannot change without losing fitness. These conserved regions were defined by bioinformatics, and a bivalent mosaic was computationally designed to increase the vaccine perfect match of potential T-cell epitopes to 80% of global HIV-1 variants; if successful, the vaccine will be suitable for global deployment. Furthermore, we maximised the inclusion of protective epitopes associated with viral control in treatment-naive HIV-1-positive individuals defined on 4 continents. These immunogens are delivered by the non-replicating simian adenovirus ChAdOx1 prime and non-replicating poxvirus MVA boost regimen, clinically proven safe and potent.MethodsThe GREAT consortium has been established to build capacity for a future efficacy trial in Zambia, around Lake Victoria and in Kenya by engaging populations at documented high risk for HIV-1 infection, despite preventive interventions, by diverse clades. We will conduct a phase I/IIa clinical trial HIV-CORE 006 to assess the safety and immunogenicity of the conserved-region vaccines, in preparation for an efficacy trial in these at-risk populations.ConclusionThe aims of the GREAT consortium are to ensure that at the completion of the programme grant, the vaccine regimen will be proven safe and potent, and the sites will be prepared to launch an appropriately designed trial to prove vaccine efficacy.

APA, Harvard, Vancouver, ISO, and other styles

12

Sileo, K. M., R. K. Wanyenze, W. Kizito, E. Reed, S. K. Brodine, H. Chemusto, W. Musoke, B. Mukasa, and S. M. Kiene. "Multi-level Determinants of Clinic Attendance and Antiretroviral Treatment Adherence Among Fishermen Living with HIV/AIDS in Communities on Lake Victoria, Uganda." AIDS and Behavior 23, no. 2 (June 29, 2018): 406–17. http://dx.doi.org/10.1007/s10461-018-2207-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Body, Amy, Jennifer F. Hoy, Allen C. Cheng, and Michelle L. Giles. "Incident hepatitis B infection subsequent to the diagnosis of HIV infection in a Melbourne cohort: missed opportunities for prevention." Sexual Health 11, no. 1 (2014): 5. http://dx.doi.org/10.1071/sh13019.

Full text

Abstract:

Background The characteristics associated with incident hepatitis B (HBV) infection in HIV-positive individuals are not well described in the Australian setting. The aim of this study is to determine the characteristics of and risk factors for HBV infection within HIV-infected individuals in a Melbourne cohort between 1985 and 2011. Methods: Individuals susceptible to HBV at their HIV diagnosis were identified using their HBV serology stored within the Victorian HIV database. Within this group, those who had a subsequent positive test for hepatitis B surface antigen or hepatitis B core antibody were identified as infected with HBV after their HIV diagnosis. Incident cases were matched with controls from the initially susceptible group who did not seroconvert for analysis. An incidence rate was calculated from the number of seroconversions and the cumulative time at risk (in 1000 patient-years of follow-up). Results: Of the 4711 patients with HIV seen more than once, 3223 had HBV testing. Of the 174 with positive HBV test results, 39 individuals met the definition of seroconversion after HIV diagnosis, representing the incident cases. The estimated HBV incidence rate was 1.81 (95% confidence interval: 1.28–2.47) per 1000 patient-years at risk. These individuals form the basis of a detailed case series and case–control study. Data collected include demographic details, immunological and virological characteristics, antiretroviral treatment and vaccination history. Conclusions: HIV-infected individuals should be screened for HBV and monitored for incident infection. Optimal control of HIV and improved vaccination coverage provide the best opportunity for prevention.

APA, Harvard, Vancouver, ISO, and other styles

14

Abdel-Magid, Ahmed F. "Treatment of HIV Infections with HIV Integrase Inhibitors." ACS Medicinal Chemistry Letters 8, no. 1 (November 23, 2016): 7–8. http://dx.doi.org/10.1021/acsmedchemlett.6b00456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Feigin, Anita, Carol El-Hayek, Margaret Hellard, Alisa Pedrana, Ellen Donnan, Christopher Fairley, B. K. Tee, and Mark Stoové. "Increases in newly acquired HIV infections in Victoria, Australia: epidemiological evidence of successful prevention?" Sexual Health 10, no. 2 (2013): 166. http://dx.doi.org/10.1071/sh12064.

Full text

Abstract:

Background Rates of newly acquired HIV notifications provide useful data for monitoring transmission trends. Methods: We describe 10-year (2001–10) trends in newly acquired HIV notifications in Victoria, Australia. We also examine recent trends in HIV testing and incidence and risk behaviours among gay and other men who have sex with men (MSM) attending four high MSM caseload clinics. Results: Between 2001 and 2010 there was a significant increasing linear trend in newly acquired HIV that was driven primarily by increases between 2009–2010. MSM accounted for 85% of newly acquired HIV notifications. Between 2007–10, the total number of HIV tests per year at the high caseload clinics increased 41% among MSM and HIV incidence declined by 52%; reported risk behaviours remained relatively stable among these MSM. Conclusion: More newly acquired HIV notifications may reflect recent increased testing among MSM; continued scrutiny of surveillance data will assess the sustained effectiveness of testing as prevention, health promotion and the contribution of risk and testing behaviours to HIV surveillance outcomes.

APA, Harvard, Vancouver, ISO, and other styles

16

Thomas, S. L., K. Lam, L. Piterman, A. Mijch, and P. A. Komesaroff. "Complementary medicine use among people living with HIV/AIDS in Victoria, Australia: practices, attitudes and perceptions." International Journal of STD & AIDS 18, no. 7 (July 1, 2007): 453–57. http://dx.doi.org/10.1258/095646207781147292.

Full text

Abstract:

There is limited evidence suggesting the underlying reasons for the use of complementary and alternative medicines (CAMs) by people with HIV/AIDS, or individual attitudes and beliefs about the use of CAMs. Using focus groups and a survey with 151 individuals attending the HIV Clinics at The Alfred Hospital, Melbourne, we aimed to provide insights into factors that influence the use of CAMs among people living with HIV/AIDS. Roughly half (49%) of the participants had used CAMs to manage their HIV/AIDs. Users of CAMs utilized a wide range of treatments in managing their condition, but costs of the CAMs meant that users were not necessarily able to use them as much as they might have liked. Use of CAMs was based on a desire to find something beneficial rather than on being dissatisfied with conventional medicine. Further research is needed into (a) the effects of CAMs and (b) the enhancement of communication and collaboration between patients, doctors and complementary medicine practitioners.

APA, Harvard, Vancouver, ISO, and other styles

17

Klepser, Michael E., and Teresa B. Klepser. "Drug Treatment of HIV-Related Opportunistic Infections." Drugs 53, no. 1 (January 1997): 40–73. http://dx.doi.org/10.2165/00003495-199753010-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Treatment strategies for HIV-related opportunistic infections." Inpharma Weekly &NA;, no. 1291 (June 2001): 2. http://dx.doi.org/10.2165/00128413-200112910-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Abdel-Magid, Ahmed F. "HIV Integrase Inhibitors for Treatment of HIV Infections and AIDS." ACS Medicinal Chemistry Letters 5, no. 2 (January 31, 2014): 102–3. http://dx.doi.org/10.1021/ml5000355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Guy, Rebecca, and Margaret Hellard. "Rising HIV infections in Victoria, the need for a new approach to preventative interventions." Sexual Health 1, no. 2 (2004): 69. http://dx.doi.org/10.1071/sh03003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Early antiretroviral treatment worth it in HIV infections." Inpharma Weekly &NA;, no. 1369 (January 2003): 10. http://dx.doi.org/10.2165/00128413-200313690-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Gazzard, B. G. "Treatment of fungal infections in HIV seropositive patients." Journal of the European Academy of Dermatology and Venereology 1, no. 5 (December 1992): S26—S30. http://dx.doi.org/10.1111/j.1468-3083.1992.tb00681.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Cohen, J. "New HIV Infections Drop, But Treatment Demands Rise." Science 330, no. 6009 (December 2, 2010): 1301. http://dx.doi.org/10.1126/science.330.6009.1301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

De Clercq, Erik. "New Perspectives for the Treatment of HIV Infections." Collection of Czechoslovak Chemical Communications 63, no. 4 (1998): 449–79. http://dx.doi.org/10.1135/cccc19980449.

Full text

Abstract:

The HIV replicative cycle reveals several virus-specific events that could function as targets for chemotherapeutic intervention. The compounds that are presently available as anti-HIV drugs are targeted at either the substrate binding site of the reverse transcriptase (zidovudine, didanosine, zalcitabine, stavudine, lamivudine) or a non-substrate binding site of the reverse transcriptase (nevirapine, delavirdine), or the viral protease (saquinavir, ritonavir, indinavir, nelfinavir). Remarkable clinical efficacy has been observed with combinations of different reverse transcriptase inhibitors and protease inhibitors. It may be anticipated that with the advent of newer and more efficient compounds the effectiveness of HIV inhibition could still be improved upon and the prospects for a definitive cure of the disease may be accomplished. An account with 107 references.

APA, Harvard, Vancouver, ISO, and other styles

25

Bagdades, E. K. "Current treatment of opportunistic infections in HIV disease." AIDS Care 3, no. 4 (October 1991): 461–66. http://dx.doi.org/10.1080/09540129108251610.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Fletcher, Courtney V. "Treatment of Herpesvirus Infections in Hiv-Infected Individuals." Annals of Pharmacotherapy 26, no. 7-8 (July 1992): 955–62. http://dx.doi.org/10.1177/106002809202600720.

Full text

Abstract:

OBJECTIVE: To discuss strategies available for the treatment of herpesvirus infections in individuals infected with HIV. DATA SOURCES: Information was obtained from controlled and uncontrolled clinical trials, abstracts, conference proceedings, and review articles. STUDY SELECTION: Emphasis was placed on controlled investigations in subjects infected with HIV. DATA EXTRACTION: Data from human studies were extracted by the author and evaluated according to the patient population studied, sample size, dosage regimen, and therapeutic response. DATA SYNTHESIS: Herpes group viruses are common opportunistic pathogens in HIV-infected individuals. Zoster, caused by varicella-zoster virus (VZV), is an early indication of the loss of cell-mediated immunity and HIV disease progression. Anorectal mucocutaneous disease is the most common manifestation caused by herpes simplex virus (HSV). Acyclovir is the drug of choice for treatment of both VZV and HSV infections. Cytomegalovirus (CMV) is the most common life-threatening viral infection in patients with AIDS; retinitis is the most frequent clinical manifestation. The response rate of CMV retinitis to initial treatment with either ganciclovir or foscarnet is equivalent, approximately 60–90 percent. Recent data suggest that the survival benefit may be greater with foscarnet. CONCLUSIONS: Advances in the development and application of antiviral drugs for herpes group viruses have made treatment and, in some cases, prevention of infections possible. Future efforts, aimed at earlier intervention and suppression of latent virus, may offer additional improvement in quality of life for the HIV-infected individual.

APA, Harvard, Vancouver, ISO, and other styles

27

Traynor, Kate. "CDC guidelines address treatment of HIV, STD infections." American Journal of Health-System Pharmacy 59, no. 13 (July 1, 2002): 1224–28. http://dx.doi.org/10.1093/ajhp/59.13.1224.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ondondo, R. O., Z. W. Ng’ang’a, S. Mpoke, M. K. Kiptoo, and E. A. Bukusi. "P3.220 Incidence and Prevalence of HIV Infections Among Fishermen Around Lake Victoria in Kisumu Kenya." Sexually Transmitted Infections 89, Suppl 1 (July 2013): A217.1—A217. http://dx.doi.org/10.1136/sextrans-2013-051184.0677.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Mallitt, Kylie-Ann, David P. Wilson, Ann McDonald, and Handan Wand. "HIV incidence trends vary between jurisdictions in Australia: an extended back-projection analysis of men who have sex with men." Sexual Health 9, no. 2 (2012): 138. http://dx.doi.org/10.1071/sh10141.

Full text

Abstract:

Background Trends in HIV diagnoses differ across Australia and are primarily driven by men who have sex with men (MSM). We use national population surveillance data to estimate the incidence of HIV infections among MSM by jurisdiction and infer the proportion of undiagnosed infections. Methods: Annual surveillance data for AIDS diagnoses, HIV diagnoses and recently acquired HIV infections were obtained from 1980 to 2009. A modified statistical back-projection method was used to reconstruct HIV incidence by jurisdiction. Results: HIV incidence among MSM peaked for all jurisdictions in the early 1980s and then declined into the early 1990s, after which incidence increased. Trends then differ between jurisdictions. In New South Wales (NSW) and South Australia, estimated HIV incidence peaked at 371 and 50 cases respectively in 2003, and has since decreased to 258 and 24 cases respectively in 2009. HIV infections in Queensland (Qld) have more than doubled over the past decade, from 84 cases in 2000 to 192 cases in 2009. Victoria and Western Australia have seen a rise in HIV incidence from 2000 to 2006 (to a peak of 250 and 38 incident cases respectively), followed by a plateau to 2009. HIV incidence in the Northern Territory, Tasmania and Australian Capital Territory have increased since 2000; however, case numbers remain small (<20 per year). The estimated proportion of HIV infections not yet diagnosed to 2009 ranges from 10% (NSW) to 18% (Qld), with an average of 12% across Australia. Conclusions: HIV diagnosis trends among MSM in Australia reflect changes in estimated incidence to 2009, and reveal the largest increase in the past 10 years in Qld.

APA, Harvard, Vancouver, ISO, and other styles

30

Ali, Qazi Masroor, Syed Hashim Raza, Ali Imran, Saba Anjum, and Maria Masroor. "Efficacy and safety of sofosbuvir plus ribavirin in treatment-naive chronic hepatitis c genotype 3 patients of South Punjab, Pakistan." International Journal of Research in Medical Sciences 8, no. 12 (November 27, 2020): 4242. http://dx.doi.org/10.18203/2320-6012.ijrms20205297.

Full text

Abstract:

Background: To evaluate the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RIB) in naive patients with chronic HCV genotype 3. The study design was open label, quasi experimental study. The study was conducted at Medical Outpatient Department of Medical Unit-1, Bahawal Victoria Hospital, affiliated with Quaid e Azam Medical College (QAMC), Bahawalpur, from April 2016 to June 2019.Methods: A total of 627 treatment-naive patients, aged above 18 years, with chronic Hepatitis C virus (HCV) genotype 3 infection were enrolled. SOF as 400 mg once a day plus weight-based RIB (1000 mg/day <75 kg and 1200 mg/day >75 kg) was given to all the study participants for 24 weeks. Qualitative polymerase chain reaction (PCR) for HCV ribonucleic acid (RNA) were done at 4 weeks to note the rapid virological response (RVR) whereas end of treatment response (ETR) was recorded at 24 weeks and sustained virological response (SVR) was noted 3 months after completion of treatment.Results: By 4th week, PCR of 524 (83.6%) patients was available, out of which, 492 (93.9%) had undetectable HCV RNA. By the end of treatment (24 weeks), PCR of 401 (64.0%) patients was available, out of which, 393 (98.0%) had undetectable HCV RNA. Data of 291 (46.4%) patients was available for SVR, 274 (94.1%) had undetectable HCV RNA. Weakness and fatigue turned out to be the commonest side effects, observed in 236 (37.6%) patients.Conclusions: Sofosbuvir was found to have good efficacy and safety in the local population of South Punjab having treatment-naïve chronic HCV genotype 3 infection.

APA, Harvard, Vancouver, ISO, and other styles

31

Wilkinson, Anna L., James McMahon, Yik-Siang Cheah, Catriona S. Bradshaw, Carol El-Hayek, and Mark Stoové. "Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia." Sexual Health 12, no. 1 (2015): 34. http://dx.doi.org/10.1071/sh14144.

Full text

Abstract:

Background An estimated 25 700 people live with diagnosed HIV (PLWH) in Australia and ~1200 newly diagnosed cases were notified in 2012. New HIV prevention strategies focus on individual uptake of treatment; however, a potential barrier is the financial burden of antiretroviral treatment (ART). We describe HIV ART dispensed and the estimated associated costs for PLWH in Victoria. Methods: A retrospective cross-sectional study of pharmacy data on ART dispensed between January 2012 and November 2013 from a hospital network, including Victoria’s largest sexual health clinic was conducted. Estimated annual patient costs of ART were calculated by the number of items dispensed per year, concession status, dispensing site and applicable co-payment. Results: A total of 60 225 dispensing records from 3903 individuals were included; this represented 83.8% of pharmaceutical benefits scheme-recorded ART dispensed in Victoria over this period. The estimated annual co-payment costs for patients without a concession card and who were collecting two medications was $433.20. One-fifth of patients (21.3%) collected four or more items, equating to an estimated annual cost of at least $866.40 without a concession card and $141.60 with a concession card. Of those dispensed four or more items, 40.4% were concession card holders. Conclusions: There may be meaningful patient costs associated with accessing ART for some PLWH. New HIV treatment-based prevention strategies need to consider financial vulnerabilities and appropriately targeted initiatives to alleviate patient costs associated with ART, ensuring they do not act as a barrier to commencement of and adherence to HIV treatment.

APA, Harvard, Vancouver, ISO, and other styles

32

Hoare, Alexander, Richard T. Gray, and David P. Wilson. "Could implementation of Australia's National Gay Men's Syphilis Action Plan have an indirect effect on the HIV epidemic?" Sexual Health 9, no. 2 (2012): 144. http://dx.doi.org/10.1071/sh10145.

Full text

Abstract:

Objectives The number of incident infections of syphilis and HIV have increased over the past decade across Australia, particularly among gay men. In other industrialised settings, syphilis epidemics have also resurged coincidentally with increases in HIV diagnoses. Sexually transmissible infections (STI) are a biologically plausible cofactor for increasing HIV transmission. We pose the question: could strategies purely targeting syphilis also have an indirect impact on HIV incidence? Methods: We developed an agent-based computer model that simulates the transmission and disease progression of HIV and syphilis among a population of sexually active gay men, calibrated to reflect the epidemics in Victoria, Australia. The model was informed by detailed behavioural data from a variety of sources and was used to investigate the potential epidemiological impact of different public health interventions. Results: Assuming that syphilis could act as a biological cofactor for HIV transmission, from no effect to increasing risk by five-fold, our model indicates that if Australia’s syphilis action plan is effectively implemented then the number of HIV infections could decrease by up to 48% over the next decade in the absence of any specific HIV interventions. Conclusion: It is plausible that effective implementation of interventions targeting syphilis epidemics can have an indirect effect of mitigating the spread of HIV. The possible effects of STI should be considered in the design, implementation and evaluation of public health strategies and programs.

APA, Harvard, Vancouver, ISO, and other styles

33

MacParland, Sonya A., Marc Bilodeau, Jason Grebely, Julie Bruneau, Curtis Cooper, Marina Klein, Selena M. Sagan, et al. "The 3rd Canadian Symposium on Hepatitis C Virus: Expanding Care in the Interferon-Free Era." Canadian Journal of Gastroenterology and Hepatology 28, no. 9 (2014): 481–87. http://dx.doi.org/10.1155/2014/704919.

Full text

Abstract:

Hepatitis C virus (HCV) currently infects approximately 250,000 individuals in Canada and causes more years of life lost than any other infectious disease in the country. In August 2011, new therapies were approved by Health Canada that have achieved higher response rates among those treated, but are poorly tolerated. By 2014/2015, short-course, well-tolerated treatments with cure rates >95% will be available. However, treatment uptake is poor due to structural, financial, geographical, cultural and social barriers. As such, ‘Barriers to access to HCV care in Canada’ is a crucial topic that must be addressed to decrease HCV disease burden and potentially eliminate HCV in Canada. Understanding how to better care for HCV-infected individuals requires integration across multiple disciplines including researchers, clinical services and policy makers to address the major populations affected by HCV including people who inject drugs, baby boomers, immigrants and Aboriginal and/or First Nations people. In 2012, the National CIHR Research Training Program in Hepatitis C organized the 1st Canadian Symposium on Hepatitis C Virus (CSHCV) in Montreal, Quebec. The 2nd CSHCV was held in 2013 in Victoria, British Columbia. Both symposia were highly successful, attracting leading international faculty with excellent attendance leading to dialogue and knowledge translation among attendees of diverse backgrounds. The current article summarizes the 3rd CSHCV, held February 2014, in Toronto, Ontario.

APA, Harvard, Vancouver, ISO, and other styles

34

Singh, Onkar, Tarun Garg, Goutam Rath, and Amit K. Goyal. "Microbicides for the Treatment of Sexually Transmitted HIV Infections." Journal of Pharmaceutics 2014 (February 12, 2014): 1–18. http://dx.doi.org/10.1155/2014/352425.

Full text

Abstract:

Approximately 34 million people were living with human immunodeficiency virus (HIV-1) at the end of 2011. From the last two decades, researchers are actively involved in the development of an effective HIV-1 treatment, but the results intended are still doubtful about the eradication of HIV. The HIV-1 virus has gone from being an “inherently untreatable” infectious agent to the one liable to be affected by a range of approved therapies. Candidate microbicides have been developed to target specific steps in the process of viral transmission. Microbicides are self-administered agents that can be applied to vaginal or rectal mucosal surfaces with the aim of preventing, or reducing, the transmission of sexually transmitted infections (STIs) including HIV-1. The development of efficient, widely available, and low-cost microbicides to prevent sexually transmitted HIV infections should be given high priority. In this review, we studied the various forms of microbicides, their mechanism of action, and their abundant approaches to control the transmission of sexually transmitted infections (STIs).

APA, Harvard, Vancouver, ISO, and other styles

35

Grebely, Jason, Marc Bilodeau, Jordan J. Feld, Julie Bruneau, Benedikt Fischer, Jennifer F. Raven, Eve Roberts, et al. "The Second Canadian Symposium on Hepatitis C Virus: A Call to Action." Canadian Journal of Gastroenterology 27, no. 11 (2013): 627–32. http://dx.doi.org/10.1155/2013/242405.

Full text

Abstract:

In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. Given that most of those already infected are aging and at risk for progressive liver disease, building research-based interdisciplinary prevention, care and treatment capacity is an urgent priority. In an effort to increase the dissemination of knowledge in Canada in this rapidly advancing field, the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC) established an annual interdisciplinary Canadian Symposium on Hepatitis C Virus. The first symposium was held in Montreal, Quebec, in 2012, and the second symposium was held in Victoria, British Columbia, in 2013. The current article presents highlights from the 2013 meeting. It summarizes recent advances in HCV research in Canada and internationally, and presents the consensus of the meeting participants that Canada would benefit from having its own national HCV strategy to identify critical gaps in policies and programs to more effectively address the challenges of expanding HCV screening and treatment.

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Etravirine approved in US for treatment-resistant HIV infections." Inpharma Weekly &NA;, no. 1622 (January 2008): 22. http://dx.doi.org/10.2165/00128413-200816220-00092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Is treatment interruption feasible in children with HIV infections?" Inpharma Weekly &NA;, no. 1474 (February 2005): 14. http://dx.doi.org/10.2165/00128413-200514740-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kuhn, Louise, and Stephanie Shiau. "The pharmacological treatment of acute HIV infections in neonates." Expert Review of Clinical Pharmacology 10, no. 12 (November 3, 2017): 1353–61. http://dx.doi.org/10.1080/17512433.2017.1398645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Developments in the treatment of children with HIV infections." Inpharma Weekly &NA;, no. 804 (September 1991): 3. http://dx.doi.org/10.2165/00128413-199108040-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bowen, Lauren N., Bryan Smith, Daniel Reich, Martha Quezado, and Avindra Nath. "HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment." Nature Reviews Neurology 12, no. 11 (October 27, 2016): 662–74. http://dx.doi.org/10.1038/nrneurol.2016.149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

LETVIN, NORMAN L., ZHENG W. CHEN, HIROSHI YAMAMOTO, and MAMORU WATANABE. "Active Immune Therapy for the Treatment of HIV Infections." AIDS Research and Human Retroviruses 8, no. 8 (August 1992): 1499. http://dx.doi.org/10.1089/aid.1992.8.1499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Cotler, Scott J., and Donald M. Jensen. "TREATMENT OF HEPATITIS C VIRUS AND HIV CO-INFECTIONS." Clinics in Liver Disease 5, no. 4 (November 2001): 1045–61. http://dx.doi.org/10.1016/s1089-3261(05)70208-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Goller, Jane L., Rebecca J. Guy, Judy Gold, Megan S. C. Lim, Carol El-Hayek, Mark A. Stoove, Isabel Bergeri, et al. "Establishing a linked sentinel surveillance system for blood-borne viruses and sexually transmissible infections: methods, system attributes and early findings." Sexual Health 7, no. 4 (2010): 425. http://dx.doi.org/10.1071/sh09116.

Full text

Abstract:

Objective: To describe the attributes and key findings from implementation of a new blood-borne virus (BBV) and sexually transmissible infection (STI) sentinel surveillance system based on routine testing at clinical sites in Victoria, Australia. Methods: The Victorian Primary Care Network for Sentinel Surveillance (VPCNSS) on BBV and STI was established in 2006 at 17 sites. Target populations included men who have sex with men (MSM), young people and injecting drug users (IDU). Sites collected demographic and risk behaviour information electronically or using paper surveys from patients undergoing routine HIV or STI (syphilis, chlamydia (Chlamydia trachomatis)) or hepatitis C virus (HCV) testing. These data were linked with laboratory results. Results: Between April 2006 and June 2008, data were received for 67 466 tests and 52 042 questionnaires. In clinics providing electronic data, >90% of individuals tested for HIV, syphilis and chlamydia had risk behaviour information collected. In other clinics, survey response rates were >85% (HIV), 43.5% (syphilis), 42.7–66.5% (chlamydia) and <20% (HCV). Data completeness was >85% for most core variables. Over time, HIV, syphilis and chlamydia testing increased in MSM, and chlamydia testing declined in females (P = 0.05). The proportion of positive tests among MSM was 1.9% for HIV and 2.1% for syphilis. Among 16–24-year-olds, the proportion positive for chlamydia was 10.7% in males and 6.9% in females. Among IDU, 19.4% of HCV tests were antibody positive. Conclusions: The VPCNSS has collected a large, rich dataset through which testing, risk behaviours and the proportion positive can be monitored in high-risk groups, offering a more comprehensive BBV and STI surveillance system for Victoria. Building system sustainability requires an ongoing focus.

APA, Harvard, Vancouver, ISO, and other styles

44

Nicolle, LE. "Sexually Transmitted Infections." Canadian Journal of Infectious Diseases and Medical Microbiology 16, no. 1 (2005): 9–10. http://dx.doi.org/10.1155/2005/958678.

Full text

Abstract:

Sexually transmitted infections (STIs) other than HIV have reappeared as an important public health problem in developed countries (1). In the late 1970s and early 1980s, research and treatment of the 'classic' STIs - gonorrhea, syphilis and chlamydia - were a major focus of infectious diseases practice and research. There were large outbreaks of syphilis in parts of Canada (2), penicillin-resistantNeisseria gonorrhoeaewas a concern (3), and high rates ofChlamydia trachomatisinfection with complications of pelvic inflammatory disease and ectopic pregnancy were being reported (4,5). Then, HIV infection emerged, with its spectre of a wasting, early death. There was no effective treatment, and safe sexual practices were embraced and adhered to by high-risk populations as the only effective way to avoid infection. These practices effectively prevented other STIs; rates of syphilis, gonorrhea and chlamydia infection plummeted in developed countries (5). For at least a decade, it appeared that HIV might be an end to all STIs, at least for some parts of the world. STIs continued unabated in developing countries, as many epidemiological and therapeutic studies explored the association of STIs with HIV infection.

APA, Harvard, Vancouver, ISO, and other styles

45

Philip Bill Okaka, Olan’g Alfred, Florence Ondieki - Mwaura, and Maurice Sakwa. "Effect of Community Health Support Systems and Technology Obsolescence on Utilization of mHealth Information by Teenagers Living with HIV/AIDS in Island Communities of Lake Victoria, Kenya." International Journal of World Policy and Development Studies, no. 73 (July 11, 2021): 45–56. http://dx.doi.org/10.32861/ijwpds.73.45.56.

Full text

Abstract:

The emergence of mHealth as an alternative access point for care and treatment is lauded by development agencies as ingenious innovation for bridging health care access for teenagers living with HIV/AIDS among detached communities like the islands of Lake Victoria. It is also presumed that mHealth transcends beyond teenagers’ concerns with location and unfriendly hours of operation of health facilities. mHealth is alleged to increase privacy and confidentiality, reduce the cost of service delivery, and loops over retrogressive cultural beliefs and attitudes exhibited by health care providers and caregivers, consequently increasing access to health information, care, and treatment. Specifically, the study sought to determine the technology obsolescence and explore community-based health support systems that facilitate suitable utilization of mHealth by teenagers living with HIV from the island communities of Lake Victoria and its effect on treatment access. To support this study, two philosophies: The theory of Reasoned Action and the Technology Adoption Lifecycle Model were applied. Anchored on cross-sectional study design, stratified sampling identified the psychosocial support groups of teenagers living with HIV. The probit model was applied to the study. With a study population of approximately 409 in Ringiti, Remba, Rusinga, Mfangano, and Mageta Islands, questionnaires were administered to 173 sampled teenagers living with HIV as a unit of analysis, and a control group made up of 30 percent of the sample ascertained effect of mHealth on treatment access. Five focus group discussions and key informant interviews of 10 and 3 were held on each Island. Multiple linear regression analysis was used to estimate the effect of the independent variables on the dependent variable. Further, the results showed that technology obsolescence and community-based health support systems had a significant effect on access to treatment by teenagers living with HIV/AIDS in the Island communities of Lake Victoria. Consequently, this study provides organizations promoting access to access to treatment by teenagers living with HIV/AIDS through mHealth. The study recommended that government and organizations involved in HIV/AIDS related activities should adopt a culture of enhancing mHealth by focusing on technology obsolescence and community-based health support systems. This could go a long way in ensuring there is improved access to treatment by teenagers living with HIV/AIDS in Island communities of Lake Victoria.

APA, Harvard, Vancouver, ISO, and other styles

46

Cooper, R. G., and P. D. Reid. "Sexually transmitted disease/HIV health-care policy and service provision in Britain." International Journal of STD & AIDS 18, no. 10 (October 1, 2007): 655–61. http://dx.doi.org/10.1258/095646207782193777.

Full text

Abstract:

The objective of this paper was to discusses historical developments of sexually transmitted disease (STD)/HIV sexual health policies in Britain, principally from the 19th to the 21st century. Repeating trends were identified and a consideration of how history addresses today's urgent need for better management of sexual health is discussed. In January 1747, the first venereal disease (VD) treatment was established at Lock Hospital, London. As the 19th century passed, sexuality emerged from a conspiracy of silence and became part of social consciousness. In Victorian times, prostitution was regarded with revulsion. Renewed medical interest in VD was brought about by improvements in medical knowledge from 1900–10. In the period 1913–17, there was a significant change in sexual health policy. From 1918, treatment centres increasingly recognized the difficulties in persuading attendees to return for a complete course of treatment. AIDS in Britain wrecked havoc in the period 1981–86 with incidences of infection in several widely differing groups and public alarm fuelled by the media. In conclusion, education, advertising and public health counselling need to be moulded effectively so that the public recognize the real risks associated with unprotected sexual intercourse.

APA, Harvard, Vancouver, ISO, and other styles

47

Duffalo, Melody L. "Fungal Opportunistic Infections in HIV Disease." Journal of Pharmacy Practice 19, no. 1 (February 2006): 17–30. http://dx.doi.org/10.1177/0897190005284095.

Full text

Abstract:

Fungal pathogens can lead to many of the complications seen in advanced HIV disease and are commonly identified in HIV-infected populations with decreased immune function. Common fungal organisms affecting individuals with AIDS include Cryptococcus neoformans, various Candida species, and Histoplasma capsulatum. While infection with these organisms can be fatal, appropriate identification and management of the condition can result in reduced mortality and the opportunity for effectivemanagement of HIV disease with highly active antiretroviral therapy. This article describes the clinical presentation and treatment of 3 fungal infections common in the immunocompromised individual with AIDS. Current antifungal therapy for themanagement of these infections is discussed. In addition, the role of newer antifungal agents in the setting of these conditions is reviewed.

APA, Harvard, Vancouver, ISO, and other styles

48

Kouanfack, Ornella Sybile D., Charles Kouanfack, Serges Clotaire Billong, Samuel N. Cumber, Claude N. Nkfusai, Fala Bede, Emerson Wepngong, Chombong Hubert, Georges N. K. Tsague Georges, and Madeleine N. Singwe. "Epidemiology of Opportunistic Infections in HIV Infected Patients on Treatment in Accredited HIV Treatment Centers in Cameroon." International Journal of Maternal and Child Health and AIDS (IJMA) 8, no. 2 (December 18, 2019): 163–72. http://dx.doi.org/10.21106/ijma.302.

Full text

Abstract:

Background: The African continent accounts for over 70% of people infected with Human Immunodeficiency Virus (HIV). The HIV sero-prevalence rate in Africa is estimated at 4.3%. In developed countries, such as France, pneumocystis is indicative of AIDS in 30% of patients; however, in Africa, pulmonary tuberculosis (TB) is the most-documented opportunistic infection (OI) and the leading cause of death in HIV-infected patients. In 2016, Cameroon had 32,000 new cases of OI and 29,000 deaths as a result of these infections. However, there is little existing data on the epidemiological profile of OIs in Cameroon, which is why we conducted this study in accredited HIV treatment centers and care/ treatment units in the two cities of Douala and Yaounde, Cameroon. Methods: This was a retrospective descriptive and analytical study carried out in 12 accredited HIV treatment centers in the cities of Yaound

APA, Harvard, Vancouver, ISO, and other styles

49

Fatmawati and Hengki Tasman. "An Optimal Treatment Control of TB-HIV Coinfection." International Journal of Mathematics and Mathematical Sciences 2016 (2016): 1–11. http://dx.doi.org/10.1155/2016/8261208.

Full text

Abstract:

An optimal control on the treatment of the transmission of tuberculosis-HIV coinfection model is proposed in this paper. We use two treatments, that is, anti-TB and antiretroviral, to control the spread of TB and HIV infections, respectively. We first present an uncontrolled TB-HIV coinfection model. The model exhibits four equilibria, namely, the disease-free, the HIV-free, the TB-free, and the coinfection equilibria. We further obtain two basic reproduction ratios corresponding to TB and HIV infections. These ratios determine the existence and stability of the equilibria of the model. The optimal control theory is then derived analytically by applying the Pontryagin Maximum Principle. The optimality system is performed numerically to illustrate the effectiveness of the treatments.

APA, Harvard, Vancouver, ISO, and other styles

50

Piché, Alain. "Gene Therapy for HIV Infections: Intracellular Immunization." Canadian Journal of Infectious Diseases 10, no. 4 (1999): 307–12. http://dx.doi.org/10.1155/1999/914379.

Full text

Abstract:

Despite significant advances in the treatment of human immunodeficiency virus (HIV) infection in the past 10 years, it remains an incurable disease. The inability of traditional drug-based therapies to inhibit HIV replication effectively for extended periods of time has stimulated intense research to develop novel approaches for this disease. Current understanding of HIV molecular biology and pathogenesis has opened the way for the development of gene therapy strategies for HIV infections. In this context, a number of intracellular immunization-based strategies have been evaluated, and some of them have reached the stage of phase I/II human clinical trials. These strategies include the use of single-chain antibodies, capsid-targeted viral inactivation, transdominant negative mutants, ribozymes, antisense oligonucleotides and RNA decoys. While a number of issues remain to be studied before intracellular immunization can be applied to the treatment of HIV infections, the significant progress already made in this field is likely to lead to clinical applications.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'HIV infections Treatment Victoria'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles